Astria Net Working Capital from 2010 to 2025
| ATXS Stock | USD 12.44 0.11 0.88% |
Net Working Capital | First Reported 2020-06-30 | Previous Quarter 250.5 M | Current Value 230 M | Quarterly Volatility 98.7 M |
Check Astria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astria Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 35.7 M, Selling And Marketing Expenses of 742.7 K or Other Operating Expenses of 56.6 M, as well as many indicators such as Price To Sales Ratio of 51.69, Dividend Yield of 0.0 or PTB Ratio of 1.49. Astria financial statements analysis is a perfect complement when working with Astria Therapeutics Valuation or Volatility modules.
Astria | Net Working Capital | Build AI portfolio with Astria Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.